JAZZ (Jazz Pharmaceuticals) Other Net Income (Loss) : $-2 Mil (TTM As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Other Net Income (Loss)?

Jazz Pharmaceuticals's Other Net Income (Loss) for the three months ended in Sep. 2024 was $-0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2 Mil.

Jazz Pharmaceuticals's quarterly Other Net Income (Loss) increased from Mar. 2024 ($-1 Mil) to Jun. 2024 ($-0 Mil) but then declined from Jun. 2024 ($-0 Mil) to Sep. 2024 ($-0 Mil).

Jazz Pharmaceuticals's annual Other Net Income (Loss) declined from Dec. 2021 ($-1 Mil) to Dec. 2022 ($-10 Mil) but then increased from Dec. 2022 ($-10 Mil) to Dec. 2023 ($-3 Mil).

Jazz Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Jazz Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Other Net Income (Loss) Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

-4.09

-2.96

-0.71

-9.92

-3.01

Jazz Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Net Income (Loss)	Get a 7-Day Free Trial															0.13	-0.46	-1.35	-0.01	-0.28

Jazz Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2 Mil.

Jazz Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (NAS:JAZZ) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

J7Z:Germany J7Z:Germany

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Executives

Bruce C Cozadd	director, officer: Executive Chairman	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 00000
Patricia Carr	officer: VP, Finance& PAO	JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Neena M Patil	officer: SVP, General Counsel	JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Mary Elizabeth Henderson	officer: SVP, Technical Operations	3170 PORTER DRIVE, PALO ALTO CA 94304
Jennifer E. Cook	director	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Mark Douglas Smith	director	C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Patrick G Enright	director, 10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Catherine A. Sohn	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Rick E Winningham	director	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heather Ann Mcsharry	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Peter Gray	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Anne Oriordan	director	HOUSE 120, TAI HANG HAU VILLAGE, LOBSTER BAY, CLEARWATER BAY K3 HK
Kenneth W O'keefe	director	C/O BEECKEN PETTY O'KEEFE & COMPANY, 131 S. DEARBORN STREET, SUITE 2800, CHICAGO IL 60603
Renee D Gala	officer: EVP & CFO	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080